Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 39INDUSTRY 13NIH 2NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1CNS 1Breast 1

Conditions

Wilms Tumor 1Sarcoma, Synovial 1Rhabdomyosarcoma 1Pleuropulmonary blastoma 1Neurofibrosarcoma 1Neuroblastoma 1Anatomic Stage II Breast Cancer AJCC v8 1

Interventions

Cisplatin 118Radiotherapy 114Cyclophosphamide 93Paclitaxel 85Gemcitabine 74Carboplatin 68Filgrastim 60Doxorubicin 57Vincristine 56Etoposide 56Docetaxel 56Fluorouracil 51Cytarabine 41Prednisone 40Methotrexate 40Leucovorin 39Dexamethasone 37Capecitabine 36Irinotecan 35Rituximab 29Oxaliplatin 28Granulocyte Colony-Stimulating Factor 27Cetuximab 26Bevacizumab 26durvalumab 24Temozolomide 24Radiotherapy, Intensity-Modulated 24Peripheral Blood Stem Cell Transplantation 24Magnetic Resonance Spectroscopy 24Surgical Procedures, Operative 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × NETWORK × Ado-Trastuzumab Emtansine × Clear all
NCT04266249 2026-05-05

CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

Eastern Cooperative Oncology Group

Phase 2 Active not recruiting
2,175 enrolled
Breast

Anatomic Stage II Breast Cancer AJCC v8

NCT02452554 2022-01-13

Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma

Children's Oncology Group

Phase 2 Completed
62 enrolled 15 charts
CNSGenitourinarySarcoma

Pleuropulmonary blastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Synovial, Neurofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡